Acción ELTX ELICIO THERAPEUTICS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Elicio Therapeutics, Inc.

Acciones

ELTX

US28657F1030

Precio de cierre Nasdaq
Otros sitios de cotización
 00:00:00 18/06/2024 		Varia. Cinco días. Varia. 1 de enero.
7,11 USD -10,90 % Gráfico intradía de Elicio Therapeutics, Inc. -12,97 % -14,75 %
23/05 Elicio Therapeutics anuncia datos preliminares del estudio de fase 1a en curso AMPLIFY-7P de ELI-002 7P en pacientes con tumores sólidos impulsados por mKRAS en la Reunión Anual de ASCO 2024 CI
15/05 Elicio Therapeutics, Inc. Resultados del primer trimestre finalizado el 31 de marzo de 2024 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics : AMPLIFY 7P, a first in human safety and efficacy trial of adjuvant mKRAS specific lymph node targeted Amphiphile ELI 002 7P vaccine in minimal residual disease positive pancreatic and colorectal cancer patients (ASCO 2024 – Scientific Poster)
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Elicio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
Elicio Therapeutics, Inc. to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing Amplify-201 Phase 1 Study of ELI-002 and ElI-008 at the AACR Annual Meeting
Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Elicio Therapeutics, Inc. announced that it has received $5.999999 million in funding from Gkcc, LLC
Elicio Therapeutics, Inc. announced that it expects to receive $5.999999 million in funding from Gkcc, LLC
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
Elicio Therapeutics, Inc. Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
Elicio Therapeutics Reports First Patient Dosed in Mid-Stage Pancreatic Cancer Trial
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
Elicio Therapeutics, Inc. Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción ELTX
  4. Noticias Elicio Therapeutics, Inc.
  5. Otros idiomas